1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hualan Biological Engineering Inc.

Hualan Biological Engineering Inc.

002007.SZ
Hualan Biological Engineering Inc.CN flagShenzhen Stock Exchange
12.69
CNY
+0.01
- -
23.17BMarket Cap
Hualan Biological Engineering Inc.
002007.SZ
(Shenzhen Stock Exchange)

Recent

price

12.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.7
0.53
0.54
0.62
0.69
0.81
1.07
1.31
1.77
2.04
2.76
2.44
2.47
2.93
2.4
2.52
2.48
Revenue per Share
0.34
0.21
0.17
0.26
0.3
0.32
0.43
0.45
0.63
0.71
0.89
0.71
0.59
0.81
0.6
0.52
0.64
Basic EPS, GAAP
0.26
0.11
0.19
0.15
0.2
0.18
0.06
0.04
0.61
0.6
0.39
0.34
0.31
0.32
0.44
0.37
-0.06
Free Cash Flow per Basic Share
0.05
0.1
0.04
0.04
0.13
0.19
0.13
0.22
0.15
0.22
0.31
0.31
0.22
0.31
0.26
0.75
0.18
Dividend per Share
0.97
1.05
1.16
1.38
1.52
1.62
1.9
2.1
2.57
3.04
3.82
4.17
4.52
5
5.24
5.04
5.32
Book Value per Share
1.29
1.38
1.52
1.76
1.89
2.03
2.33
2.55
3.06
3.67
4.34
4.85
6.51
7.17
7.39
7.15
7.46
Tangible Book Value per Share
1,798
1,798
1,798
1,801
1,813
1,814
1,814
1,814
1,814
1,817
1,818
1,821
1,825
1,824
1,826
1,826
1,826
Basic Weighted Avg Shares
1,262
961
972
1,118
1,243
1,472
1,935
2,368
3,217
3,700
5,023
4,436
4,517
5,342
4,379
4,595
4,525
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
38.15
- -
- -
- -
- -
- -
- -
- -
- -
30.22
Operating Margin (%)
69
81
94
102
113
117
144
146
139
161
182
196
273
260
261
276
- -
Depreciation Expense
612
371
300
475
538
589
780
821
1,140
1,283
1,613
1,299
1,076
1,482
1,088
940
1,164
Net Income, GAAP
15.07
16.19
15.81
15.24
14.21
15.96
14.69
12.97
12.97
14.37
14.12
13.87
12.66
15.21
13.68
14.77
13.19
Effective Tax Rate (%)
48.54
38.56
30.83
42.53
43.3
40.03
40.33
34.66
35.42
34.69
32.11
29.28
23.83
27.74
24.84
20.47
25.71
Profit Margin (%)
1,570
1,692
1,660
2,022
2,373
2,513
2,967
3,292
4,062
4,990
5,595
4,636
5,929
6,745
7,256
7,064
7,870
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
190
309
9
9
8
8
LT Debt
2,406
2,581
2,831
3,311
3,636
3,884
4,435
4,842
5,773
6,884
8,100
9,064
12,210
13,421
13,847
13,391
13,970
Total Equity
- -
- -
- -
- -
- -
- -
- -
17.01
- -
- -
- -
- -
- -
- -
- -
- -
8.34
Return on Invested Capital (%)
30.63
16.9
13.02
18.56
18.53
19.39
23.13
21.74
24.13
22.15
20.1
13.48
9.09
10.38
8.37
7.41
9.23
Return on Capital (%)
40.43
20.42
15.05
20.78
20.6
20.7
24.45
22.63
26.86
25.18
25.85
17.86
13.59
17.07
11.65
10.02
12.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
900
1,080
280
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,829
1,829
1,827
Market Capitalization
30,824
28,356
28,611

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
9,616
10,550
9,336
Cash, Cash Equivalents & STI
3,255
3,649
2,927
Accounts Receivable, Net
1,798
1,871
1,581
Inventories
2,029
2,232
2,303
Total Current Liabilities
2,360
2,368
1,466
Payables & Accruals
- -
- -
- -
ST Debt
900
1,080
280
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.59%
11.28%
-3.29%
Free Cash Flow
137.51%
0.9%
-15.33%
Net Income, GAAP
7.57%
-7.82%
-13.55%
Sales/Revenue/Turnover
13.58%
-0.94%
4.93%
Total Cash Common Dividend
27.96%
36.93%
191.02%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
787
865
1,838
889
4,379
2025
868
931
1,216
- -
4,595
2026
762
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
- -
- -
- -
0.6
2025
0.17
- -
- -
- -
0.52
2026
0.13
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.26
2025
0.05
- -
- -
- -
0.75
2026
- -
- -
- -
- -
- -
Similar Companies
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
PHAXIAM Therapeutics S.A. (PHXM)
Photocure ASA (PHCUF)
Jasper Therapeutics, Inc. (JSPRW)
Acrux Limited (ACR.AX)
BELLUS Health Inc. (BLU)
Business
Hualan Biological Engineering Inc. (002007.SZ) researches, develops, produces and commercializes blood products, vaccines, and genetic engineering products in China; its core blood products include human albumin, intravenous human immunoglobulin, human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen; vaccines comprise influenza vaccine (split virion, inactivated, adult and children), quadrivalent influenza vaccine (split virion, inactivated, adult), group ACYW135 meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine, group A and group C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine, and adsorbed tetanus vaccine. The company operates primarily in the biopharmaceutical sector, targeting healthcare providers, hospitals and public health programs with plasma-derived biologics, viral and bacterial vaccines, and recombinant proteins; it maintains plasma collection stations, poultry breeding for R&D, and contract manufacturing organization services. Founded in 1992 and headquartered in Xinxiang City, Henan Province, China, Hualan Biological Engineering Inc. holds subsidiaries such as Hualan Biological Vaccine Inc. for vaccine production. Recent developments include investing CNY 200 million in July 2025 for a 40% stake in Hualan Genetic Engineering Co., Ltd. during a CNY 500 million equity funding round that increased the subsidiary's capital to CNY 700 million; over the past two years, the company acquired three biopharmaceutical firms for around CNY 1 billion to expand its portfolio and distribution, alongside a partnership with a leading European pharmaceutical company for new biologics development projected to add CNY 300 million in annual revenue.